Glox Therapeutics
Glox Therapeutics creates precision antibiotics through the use of engineered protein bacteriocins.
Operating in biotechnology, product research based in Europe, Middle East, and Africa (EMEA), Glox Therapeutics was founded in 2023.
The company sits in the biotechnology, product research segment, where it competes on its core product or service.
The company is recorded as being based in Europe, Middle East, and Africa (EMEA).
It is recorded at the Seed stage.
Recorded headcount: c_00001_00010 employees.
Public records show total funding of about $4.3M.
| Sector | Biotechnology, Product Research |
|---|---|
| Headquarters | Europe, Middle East, and Africa (EMEA) |
| Founded | 2023 |
| Employees | c_00001_00010 |
| Stage | seed |
| Total funding | $4,300,000 |
Website: gloxtherapeutics.com
Sign in to view the contact information we hold for Glox Therapeutics.
Create a free account
Create a free account